10-Q: Kairos Pharma Reports Q3 2026 Results, Faces Going Concern Doubt

Kairos Pharma, Ltd. filed its Q3 2026 10-Q, detailing continued operating losses and substantial doubt regarding its ability to continue as a going concern, while advancing its oncology therapeutics.

Summary

• Kairos Pharma, Ltd. reported its financial results for the nine months ended September 30, 2026, showing continued operating losses and a net loss of $5.026 million.
• The company has an accumulated deficit of $19.288 million and faces substantial doubt about its ability to continue as a going concern, as noted by its independent auditors.
• Cash and cash equivalents stood at $3.125 million as of September 30, 2026, with management expecting this may not be adequate to fund operations for the next 12 months.
• Research and development expenses increased to $2.195 million for the nine months ended September 30, 2026, up from $1.597 million in the prior year period, primarily due to Phase 2 trials.
• General and administrative expenses also rose to $2.921 million from $2.560 million, with notable increases in stock-related expenses and officer compensation.
• The company completed a 1-for-7 reverse stock split effective September 1, 2026.
• Subsequent to the quarter, Kairos Pharma raised an additional $1.558 million through its At-the-Market (ATM) offering.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the company's continued operating losses, substantial doubt about its going concern status, and lack of product revenue, despite ongoing development efforts.

Positives

• Continued progress in advancing product candidates through preclinical and clinical development for oncology treatments.
• Successful completion of a 1-for-7 reverse stock split to meet potential listing requirements.
• Raised $1.870 million in gross proceeds through its ATM offering during the nine months ended September 30, 2026, with an additional $1.558 million raised post-period.
• Entered into a Pharmaceutical Development Services Agreement with Brammer Bio MA, LLC (Patheon) for manufacturing clinical supply of ENV-105 sterile liquid vials.

Negatives

• Significant operating losses continue, with a net loss of $5.026 million for the nine months ended September 30, 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern, as indicated by management and the independent auditor.
• The company's existing cash balance of $3.125 million may not be sufficient to fund operations for the next 12 months.
• Research and development expenses increased by 37.4% to $2.195 million for the nine months ended September 30, 2026.
• General and administrative expenses increased by 14.1% to $2.921 million for the nine months ended September 30, 2026.
• The company has not generated any product sales revenue to date.
• Disclosure controls and procedures were found to be not effective at a reasonable assurance level.
• A material weakness in internal controls related to segregation of duties and review procedures persists.

Risks

• The company's ability to continue as a going concern is dependent on raising additional funds and implementing its strategies.
• Failure to raise sufficient capital could lead to delays or elimination of product development or commercialization efforts.
• Potential dilution for shareholders if additional equity financing is pursued.
• The company may be unable to satisfy evolving NYSE American listing standards, risking delisting.
• The outcome and cost of clinical trials are highly uncertain and could significantly impact development timelines and expenses.
• The company cannot reasonably estimate the amounts necessary to successfully complete development and commercialization of its product candidates.
• The company may not receive some or all of the available proceeds from its equity line of credit or ATM offering due to factors outside its control.

Future Outlook

The company expects to continue incurring significant and increasing expenses and operating losses for the foreseeable future as it advances its product candidates through development, seeks regulatory approval, and operates as a public company. It anticipates needing substantial additional funding through equity offerings, debt financings, or collaborations. Management estimates its current cash balance may not be adequate to fund planned operating expenses and capital expenditures for at least the next 12 months.

Management Comments

• "We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance."
• "Our mission is to advance our portfolio of innovative therapeutics to reverse key mechanisms of therapeutic resistance and immune suppression and transform the way cancer is treated."
• "We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future... We will not generate revenue from product sales unless and until we successfully complete our clinical trials and obtain regulatory approval for our product candidates."
• "We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to raise capital or enter into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition."

Industry Context

StockSavvy.ai notes that Kairos Pharma operates in the highly competitive and capital-intensive biotechnology sector, focusing on oncology. The company's reliance on future financing and the long, uncertain path to drug approval are common challenges in this industry. The increased R&D spending aligns with typical progression through clinical trial phases, but the lack of revenue and going concern issues are significant headwinds.

Comparison to Industry Standards

• Many early-stage biotechnology companies, like Kairos Pharma, experience significant operating losses and rely heavily on external financing for extended periods before achieving profitability, if ever.
• The typical development timeline for a new drug can span over a decade and cost hundreds of millions to billions of dollars, making substantial funding rounds and strategic partnerships crucial for survival and success.
• Companies in this sector often face scrutiny regarding their cash runway and ability to meet listing requirements of exchanges like NYSE American, as highlighted by Kairos Pharma's risk factors.
• The increasing R&D expenses are consistent with industry trends for companies advancing multiple product candidates through clinical trials, such as those seen with companies like Moderna or BioNTech during their development phases.

Corporate Governance

Legal Proceedings

• The company is not presently party to any pending or threatened legal proceedings or claims that are believed to have a material adverse effect on its business, financial condition, or operating results.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity financings; risk of delisting from NYSE American impacting stock liquidity and value.
• Creditors: The company's going concern status and reliance on future financing may impact its ability to meet debt obligations if any.
• Employees: Continued operations and advancement of product candidates are dependent on successful fundraising.
• Suppliers: Continued engagement with service providers like Lonza and Patheon is contingent on the company's financial stability.

Next Steps

• Continue advancing product candidates through preclinical and clinical development.
• Seek regulatory approval for current and future product candidates.
• Continue to raise additional funds through equity offerings, debt financings, or collaborations.
• Monitor and address material weaknesses in internal controls over financial reporting.
• Continue to comply with NYSE American listing requirements.

Key Dates

Recommendation

The company exhibits significant financial distress with recurring operating losses, a substantial accumulated deficit, and explicit doubt about its ability to continue as a going concern. While R&D progress is noted, the lack of revenue, increasing expenses, and potential dilution from necessary capital raises present considerable downside risk. The ongoing material weaknesses in internal controls further add to the risk profile, making it difficult to recommend holding or buying at this stage.

Keywords

biotechnology, oncology, immunotherapy, cell therapy, clinical trials, drug development, FDA approval, capital raise